Evaluation of tirzepatide as an adjunct to buprenorphine (TAB) for the treatment of opioid use disorder is a pragmatic, multi-site, double-blind, randomized, placebo-controlled trial.
The study is examining the effects of an investigational use of tirzepatide (marketed as Monjouro and Zepound) on staying in treatment with medications for opioid use disorder (MOUD). Tirzepatize is approved by the FDA for type 2 diabetes and weight management.
The study is looking for people are are:
-at least 18 years old
-have recently enrolled in Medication for Opioid Use Disorder with buprenorphine (e.g. Suboxone, Zubsolv, etc.)
Who is doing the study?
CTN-0152 is a national, multi-site clinical research trial headed by T. John Winhusen, PhD, at the University of Cincinnati. The study is being conducted through the National Institute on Drug Abuse’s Clinical Trials Network.
Jessica Young, MD, is the principal investigator at Vanderbilt Health, which is one of the sites participating in CTN-0152.
Contact the Vanderbilt Health team at 615-587-9669 or vumc.ctn152tab@vumc.org if you’re interested in being in the study or would like more information.